All In MedTech

FDA Clearance Tracker · P210005-S005

IC-8 Apthera Intraocular Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 31, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 31, 2023

Approved

Time to decision

60 days

Received Jun 1, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P210005-S005
Device name
IC-8 Apthera Intraocular Lens
Applicant location
Irvine, CA
Received
Jun 1, 2023
Decided
Jul 31, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P210005

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code POE

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site located at Bausch & Lomb, 21 N. Park Place Blvd., Clearwater, Florida, 33759 for the following functions: 1) Receiving inspections of device raw materials/ subassemblies 2) Shipping and handling of device raw materials/subassemblies 3) Lot release and documentation review of finished devices 4) Handling, storage, preservation and distribution of finished devices.

Source documents

Other decisions for Acu Focus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.